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Abstract
The oxidative behavior of viloxazine was studied at a glassy carbon electrode in different buffer systems using cyclic,
differential pulse and square-wave voltammetry. The oxidation process was shown to be diffusion-controlled and
irreversible over the studied pH. The voltammetric study of the model compounds, 2-ethoxyanisole and morpholine,
associated with quantum mechanical (DFT) calculations, allowed to elucidate the oxidation mechanism of viloxazine.
An analytical method was developed for the quantification of viloxazine using an acetate pH 5 buffer solution as a
supporting electrolyte. A linear response was obtained in the range 7 to 45 mM, with a detection limit of 0.8 mM.
Validation parameters such as sensitivity, precision and accuracy were evaluated. The proposed method was
successfully applied to the determination of viloxazine in pharmaceutical formulations and in human serum. The
results were statistically compared with those obtained through an established high-performance liquid chromatog-
raphy technique, no significant differences having been found between the two methods.
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1. Introduction
Depression is becoming a quite common psychological
disorder, affecting millions of people worldwide. The first
drugs used to treat depressionwere tricyclic antidepressants,
such as amitriptyline and imipramine, as well as the
monoamine oxidase inhibitors. The side-effects, toxicity
and severe drug-drug interactions of these types of com-
pounds lead to the introduction of new antidepressants, in
the light of the remarkable advances in the understanding of
the central nervous system (CNS). Nowadays, an important
group of such drugs comprises the selective noradrenalin
reuptake inhibitors, including viloxazine.
Viloxazine, 2-[(2-ethoxyphenoxy)methyl] morpholine
(VX, Fig. 1), is a member of a series of compounds which
were synthesized in order to exploit the central nervous
system activity of the aryloxypropanolamine type of b-
adrenoreceptor antagonist.Viloxazine is indicated for use in
the treatment of all types of depression. It may be
particularly useful in the enderly when they have a tendency
to delirium, as long as they have no history of proneness to
nausea. In contrast to other antidepressants (e.g., imipr-
amine), viloxazine has minimal sedative anticholinergic or
adrenergic effects in humans and it acts partly as an
amphetamine-type CNS stimulant, although there is little
evidenceof dependenceornon-durability of drug effects [1].
Viloxazine is rapidly and almost completely absorbed
following oral administration. The unchanged drug is the
major component found in blood at all times and it is
probably the pharmacologically active agent. It has a short
plasma half-life and is extensively metabolized and rapidly
excreted through the kidneys [1].
Analytical methods for the detection of antidepressants
are not only of interest in the field of clinical toxicology but
also in forensics, as this type of compounds is often involved
in intoxication events [2 – 4]. The development of new
quantitative techniques for drug assessment is thus of the
utmost importance. These may also be used for monitoring
patient compliance and to establish relationships between
blood concentration and the therapeutic effects, which are
not always fully understood. Moreover, therapeutic drug
monitoring can provide valuable information for attaining a
rational and cost-effective use of psychiatric drugs [4 – 6].
Electroanalytical methods have long been used for the
determination of a wide range of drug compounds due to
their simplicity, low cost and relatively short analysis time
when compared to other techniques. Furthermore, the
knowledge of the electrochemical properties of a drug is an
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important pharmaceutical tool since it can be relevant to
understand its metabolic fate or in vivo redox processes and
pharmacological activity [7 – 9].
Very few studies are to be found in the literature on the
quantification of viloxazine, most of these relying on
chromatographic methods [10 – 13]. To this date, no infor-
mation on the electrochemical redox properties of this drug
has been reported, and no analytical method has been
proposed for its determination in pharmaceutical prepara-
tions or in human fluids.
The purpose of the present study is to carry out a detailed
investigation on the electrochemical behavior of viloxazine
at a glassy carbon electrode using cyclic, differential pulse
and square-wave voltammetry. In order to fully elucidate its
oxidation mechanism, the voltammetric study of the model
compounds 2-ethoxyanisole (EA) and morpholine (MP)
(Fig. 1) was also undertaken. Also, in an effort to further
clarify the electronic properties of the compounds under
study, quantum mechanical calculations, at the density
functional theory (DFT) level, were performed. As a final
goal, a simple, rapid, sensitive and reliable electroanalytical
procedure is proposed for the determination of viloxazine in
pharmaceutical dosage forms and in human blood serum.
2. Experimental
2.1. Apparatus
Voltammetric experiments were performed using an Auto-
lab PGSTAT 12 potentiostat/galvanostat (EcoChemie,
Netherlands) associated to an one-compartment glass
electrochemical cell equippedwith a three-electrode system
consisting of a glassy carbon working electrode (GCE) (d¼
2 mm), a platinum wire counter electrode and an Ag/AgCl
saturated KCl reference electrode. The glassy carbon work-
ing electrode was polished manually with aqueous slurry of
alumina powder (BDH)on amicrocloth pad and rinsedwith
water before use. All measurements were made at room
temperature.
The optimum instrumental parameters to be used in the
square-wave voltammetric (SWV) quantification were
chosen by studying the variation of the peak current (Ip)
with the square-wave frequency (f), pulse amplitude (Es)
and ionic strength (I). The system was optimized, partic-
ularly in respect of maximum peak current and reproduci-
bility.
A Crison pH-meter with glass electrode was used for the
pH measurements (Crison, Barcelona, Spain).
The HPLC method [11] was performed using a HPLC/
DAD system consisting in a Jasco instrument (pumpsmodel
880-PU and solvent mixing model 880-30, Tokyo, Japan),
equipped with a commercially prepacked Nucleosil RP-18
analytical column (250 mm 4.6 mm, 5 mm, Macherey-
Nagel, DQren, Germany) and UV detection (Jasco model
875-UV) at the maximum wavelength determined by the
analysis of the UV spectrum (220 nm). The mobile phase
was 20 mM phosphate buffer pH 3.8 – acetonitrile, at a flow
rate of 1.0 mL per minute at room temperature. The
acetonitrile content of the mobile phase was increased
linearly from25% to 40%during the first 10 min and then to
44% in 8 min.
The chromatographic data was processed in a Compaq
computer, fitted with CSW 1.7 software (DataApex, Czech
Republic).
2.2. Chemicals and Standards
Viloxazine hydrochloride was provided by AstraZeneca
(Queluz, Portugal). Morpholine and 2-ethoxyanisole were
purchased from Sigma-Aldrich Qumica (Sintra, Portugal).
Analytical grade reagents purchased from Merck (Darm-
stadt, Germany) were used without additional purification.
Vivalan, labelled to contain 100 mg viloxazine per tablet,
was a gift from AstraZeneca.
Deionized water (conductivity< 0.1 mS cm1) was used
throughout the experiments. Buffer solutions employed for
voltammetric determinations were 0.2 M in the pH range
1.2 – 12.2.
HPLC-grade acetonitrile was obtained from Merck.
Phosphate buffer 20 mM was prepared in deionized water
and the pH was adjusted to 3.8 with 10% ortho-phosphoric
acid. Prior to use, the solvents were filtered through a 0.45-
mm filter.
A standard stock solution of viloxazine (2 mM) was
prepared in deionized water. In a typical run, 10 mL of
supporting electrolyte was transferred to the electrochem-
ical cell and the required volume of the standard stock
Fig. 1. Chemical formulae of viloxazine, 2-ethoxyanisole and
morpholine.
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solution of viloxazine was added. For calibration curves,
standard solutions were prepared in the voltammetric cell,
adding accurate volumes of the stock standard solution to
the selected acetate pH 5 supporting electrolyte in order to
obtain concentrations between 7 and 45 mM.The calibration
curve for SWVanalysis was constructed by plotting the peak
current against the viloxazine concentration (7.4, 14.8, 22.0,
29.1, 36.1 and 43.1 mM). The limit of quantification (LOQ)
and the limit of detection (LOD) were calculated according
toUSPguidelines [14].AS/N ratio of ten and threewas used
respectively. Method precision was checked at different
days, within day (n¼ 5) and between days (n¼ 5) for three
different concentrations. The accuracy of the proposed
method was determined by comparing the results obtained
with those from a previously published HPLC method [14].
The precision and accuracy of the analytical method was
also described by the use of relative errors (Bias%).
2.3. Analysis of Pharmaceutical Dosage Form
For viloxazine determination in pharmaceuticals, an
amount of ten tablets were weighed and ground to a
homogeneous fine powder in a mortar. An accurately
weighed portion equivalent to a stock solution of a concen-
tration about 2 mM was transferred to a volumetric flask
and dissolved with deionized water. The mixture was
sonicated for 5 min to effect complete dissolution and
filtered to remove any remaining insoluble matter.Working
solutions of the pharmaceutical formulation were prepared
exactly as the standard solutions.
2.4. Analysis of Spiked Serum Samples
Human serum samples were collected from healthy volun-
teers and stored frozen until the assay. An aliquot volume of
sample was fortified with viloxazine and dissolved in
deionized water to achieve final concentration of 2 mM.
The mixture was treated with 0.7 mL of methanol as serum
denaturating and precipitating agent, and then the volume
was completed to 2 mL with the same serum sample. The
tubes were vortexed for 5 min and then centrifuged for
10 min at 4000 rpm for removing of protein residues. The
supernatant was taken carefully. Appropriate volumes of
this solution were added to acetate pH 5 supporting electro-
lyte and the voltammograms were then recorded.
The concentration of viloxazine in the human serum
samples varied in the range of 10 to 45 mM. For the recovery
studies the amount of viloxazine in spiked human serum
samples was calculated from the related calibration equa-
tion.
Methanol and acetonitrile, in different amounts, were
tested as serum protein precipitating agents. Yet, the best
results were obtained using 0.7 mL of methanol.
2.5. Quantum Mechanical Calculations
The quantum mechanical calculations, geometry optimiza-
tion and calculation of the harmonic vibrational frequencies,
were performed using the GAUSSIAN 03W program [15],
within the Density Functional Theory (DFT) approach in
order to properly represent the electron correlation effects.
The B3LYP hybrid method, which includes a mixture of HF
and DFT exchange terms and the gradient-corrected
correlation functional of Lee, Yang and Parr [16, 17] as
proposed and parameterized by Becke [18, 19], was used,
alongwith the double-zeta split valence basis set 6-31G* [20,
21].
Molecular geometries were fully optimized by the Berny
algorithm, using redundant internal coordinates [22]: The
bond lengths to within ca. 0.1 pm and the bond angles to
within ca. 0.18. The final root-mean-square (rms) gradients
were always less than 3 104 hartree bohr1 or hartree
radian1. No geometrical constraints were imposed on the
molecules under study.
Atomic charges were also calculated and a population
analysis was undertaken, yielding the highest occupied and
lowest unoccupied molecular orbitals for the systems
studied (HOMO and LUMO, respectively).
3. Results and Discussion
3.1. Voltammetric Studies
No electrochemical data is to be found in the literature
concerning the electrode behavior of viloxazine. The
voltammetric study presently reported, using different
electrochemical techniques, was therefore performed in
a broad pH range (1.2 – 12.2), using a glassy carbon
electrode.
The differential pulse voltammetric (DPV) behavior of
viloxazine yielded one anodic wave, Ep¼þ1.20 V, starting
at pH 1 (Fig. 2), as a result of an oxidation process occurring
on the aromatic nucleus of themolecule.As the pH increase,
a second poorly resolved shoulder appears, Ep¼þ1.10 V
near pH 7 (Fig. 2a), corresponding to the oxidation of the
secondary amine group of themorpholine moiety. The peak
potential (Ep) of the main oxidation process does not
dependon the solutionpH, since no significant variationwas
observed (Fig. 2b).
To better comprehend the oxidative behavior of vilox-
azine, the voltammetric assessment was extended to the
study of the model compounds 2-ethoxyanisole and mor-
pholine (Fig. 1).
TheDPV behavior of 2-ethoxyanisole yielded one anodic
wave, Ep¼þ1.15 V, starting at pH 1 (Fig. 3a). The peak
potentials (Ep) obtained does not depend on the solution
pH, since no significant variation was observed upon pH
variation. At some acidic pHTs a second poorly resolved
wave is seen at Ep¼þ1.40 V. This oxidative pattern closely
matches the behavior observed for viloxazine, in particular
considering its main oxidation process (Fig. 4).
1456 E. M. P. J. Garrido et al.
Electroanalysis 20, 2008, No. 13, 1454 – 1462 www.electroanalysis.wiley-vch.de J 2008 WILEY-VCH Verlag GmbH&Co. KGaA, Weinheim
These results are consistent with the data previously
reported on alkoxylbenzenes [23 – 25], which indicates that
oxidation proceeds via formation of a cation-radical inter-
mediate. Thus, it seems reasonable to suppose that vilox-
azine oxidation occurs at the aromatic nucleus, through a
one-electron transfer, yielding an unstable cation-radical
(Scheme 1). The second oxidation wave observed at acidic
pHTs for 2-ethoxyanisole, not detected for viloxazine, must
then be related to the oxidation of the species resulting from
the formation and dimerization of the initial cation radical
[24, 25].
The differential pulse voltammetric study of morpholine
yielded an anodic shoulder, Ep¼þ0.98 V, starting at pH 8
(Fig. 3b). The appearance of this peak is connected with the
acid-base properties of morpholine (pKa¼ 8.4). In fact, at
this pH deprotonation of the amine group occurs and, as a
result, an oxidative process can take place (due to the
existence of an electron lone pair). Oncemore, these results
allow to validate the data obtained for viloxazine that has a
similar pKa (pKa¼ 8.13) (Fig. 4).Hence, itmay be proposed
that the second anodic process occurring in viloxazine is
related to the oxidation of the secondary amine group of the
heterocyclic nucleus (Scheme 1).
Regarding the analytical application of this type of
studies, the influence of the pH on the viloxazine peak
current at a glassy carbon electrode was also investigated,
using DPV. The plot of Ip vs. pH indicates that the peak
current reaches a maximum for pH 5 (Fig. 2b). The exper-
imental results also showed that the curve shapes are better
defined in pH 5 acetate buffer as compared to Britton –
Robinson buffers. Accordingly, this buffer was chosen as
the best supporting electrolyte and was used throughout the
analytical study.
Cyclic voltammetric measurements performed for
0.2 mM viloxazine solutions evidenced the irreversible
Fig. 2. a) 3D plot and b) plots of Ep (filled symbols) and Ip (open
symbols) vs. pH from differential pulse voltammograms of 0.2 mM
solutions of viloxazine in different buffer electrolytes as a function
of pH. Scan rate 5 mV s1.
Scheme 1.
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nature of the oxidation process at the glassy carbon
electrode, as no peaks were observed in the reverse scans
(Fig. 5). The irreversibility was also studied through a Tafel
treatment of voltammetric curves, which yielded a an value
of 0.41, indicating the irreversibility of the electron-transfer
process [26].
The study of the influence of the scan rate from 0.01 to
0.5 V s1 for the viloxazine oxidation allowed to conclude
that the peak current (Ip) changes linearly with the scan rate
(v), according to the equation Ip¼Av x. The regression of log
Ip vs. log v yielded a line of slope 0.48, typical of a diffusion-
controlled process [27]. Increasing the scan rate, the peak
potential shifted towards more positive values, as expected
for an irreversible oxidation reaction. These studies reveal
that no important electrode fouling and surface deactivation
effects occur under the experimental conditions used.
3.2. DFT Calculations
Quantum mechanical (DFT) calculations were performed
for morpholine (MP),N-protonated morpholine (MPH), 2-
ethoxyanisole (EA), viloxazine (VX) and N-protonated
viloxazine (VXH), in order to complement the results
obtained by electrochemical methods, thus providing rele-
vant information on the viloxazine oxidationmechanism. In
Fig. 3. 3D plot from differential pulse voltammograms of
0.2 mM solutions of a) 2-ethoxyanisole and b) morpholine in
different buffer electrolytes as a function of pH. Scan rate 5 mV
s1.
Fig. 4. Differential pulse voltammograms of a 0.2 mM solutions
of (—) viloxazine, (- - -) 2-ethoxyanisole and ( · · · · ) morpholine in
pH 9 buffer electrolyte. Scan rate 5 mV s1.
Fig. 5. Cyclic voltammogram for 0.2 mM solution of viloxazine
in pH 5 acetate buffer. Scan rate 100 mV s1.
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fact, the determination of the structural characteristics and
the electronic-density distribution within a molecule is
valuable for the understanding of its electrochemical
behavior.
The lowest energy optimized geometries calculated for
viloxazine, 2-ethoxyanisole andmorpholine are represented
in Figure 6, and the corresponding and most significant
Mulliken atomic charges are depicted in Table 1. The
analysis of charge populations evidence that the nitrogen
from the morpholine moiety of viloxazine, as well as atoms
C11 to C14 from the aromatic ring (Fig. 6) have a higher
electron density than the rest of the molecule, thus
confirming their vital role in the oxidation process of
viloxazine.
Apart from an accurate determination of the ground state
geometry of viloxazine, the nature of its frontier molecular
orbitals (HOMO and LUMO) was also studied, since these
are directly involved in the reactivity (electrophilicity/
nucleophilicity) of the molecule, thus ruling its electro-
chemical behavior. Actually, electrochemical reactions can
be achieved by a direct electron transfer, at a particular
potential value. If electrons are transferred from the
HOMO of a compound, a correlation is expected to exist
between the EHOMO and the oxidation potential, because,
according to KoopmansT theorem, the negatives of the
orbital energies in the ground state are equal to the
ionization potentials. Thus, it may be assumed that the
oxidative processes undergone by a certain system are
driven by the electron density profile of its HOMOTs.
Fig. 6. Schematic representation of the most stable calculated geometries for morpholine (A), 2-ethoxyanisole (B), and viloxazine (C).
B3LYP/6-31G* level of calculation. The atom numbering for viloxazine is included.
Table 1. Atomic Mulliken charges calculated (B3LYP/6-31G*)
for morpholine (MP), N-protonated morpholine (MPH), 2-
ethoxyanisole (EA), viloxazine (VX) and N-protonated vilox-
azine (VXH).
Atom [a] MP MPH EA VX VXH
O2 0.49 0.46 – 0.50 0.49
N5 0.61 0.48 – 0.56 0.26
C11 0.20 0.20
C12 0.14 0.14
C13 0.14 0.14
C14 0.20 0.20
S C11C14 0.68 0.68
C15 0.33 0.34
C16 0.34 0.34
O21 0.50 0.52
O22 0.51 0.51
[a] Atoms are numbered according to Figure 6.
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The population analysis presently carried out for vilox-
azine at the DFT level showed that in the protonated
molecule the HOMO and HOMO-1 (highest occupied and
second highest occupied molecular orbitals, respectively)
are localized on the carbons of the aromatic ring (Fig. 7a).
For unprotonated viloxazine, in turn, while HOMO is still
centered on the aromatic ring, HOMO-1 is delocalized to
the morpholine moiety (Fig. 7b). These results corroborate
the data yielded by the voltammetric techniques, which
allows to conclude that the anodic oxidative processes
occurring for viloxazine are mainly due to a one-electron
transfer at the aromatic nucleus coupled to the oxidation of
the secondary amine group from the morpholine moiety.
3.3. Analytical Applications
On the basis of the voltammetric behavior of viloxazine, a
quantitative analytical method was developed to determine
the drug content in different types of samples. To select the
best electrochemical method for this purpose, the anodic
peaks obtained by differential pulse and square-wave
voltammetry (SWV) were compared. SWV was found to
be the faster method, gives the best ratio of peak-to-
background current and provide sharper and better defined
peaks, leading to an enhanced resolution.
Optimization of the SWV parameters regarding peak
definition and current was accomplished using f¼ 175 Hz,
Es¼ 50 mVand I¼ 0.2 M (see Sec. 2).
Under the described experimental parameters, linear
calibration plots were obtained for viloxazine in the
concentration range 7 to 45 mM. Analytical data for the
calibration graphs are summarised in Table 2. The limit of
detection (LOD) and the limit of quantification (LOQ),
obtained after five runs, are also presented in Table 2.
The precision of the method was evaluated by repeatedly
(n¼ 5) measuring viloxazine, at three levels of concentra-
tion (10, 25 and 40 mM) within a day and over five
consecutive days (Table 2).
3.4. Determination of Viloxazine in Tablets
In order to evaluate the applicability of the proposed
method, a commercial sample containing viloxazine (Viva-
lan) was analyzed. Furthermore, the reliability of this
method was tested by analyzing Vivalan through a previ-
ously reported HPLC technique [11].
For the SWV and HPLC methods, five different inde-
pendent measurements were carried out. These results,
which summarised inTable 3, show that SWVmethod yields
an average concentration which is in good agreement with
the label claim (100 mg/tablet). Moreover, values obtained
by SWV fitted reasonably well with those yielded by
chromatography.
The F- and t-test were carried out on the data and
statistically examined the validity of the obtained results.
For a confidence level of 95%, the values of t- and F-tests
Fig. 7. Electronic structures calculated (B3LYP/6-31G*) for the a) N-protonated viloxazine and b) viloxazine molecule highest
occupied molecular orbital (HOMO) and second highest occupied molecular orbital (HOMO-1).
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were less than those of theoretical values, showing that there
is no significant difference between the proposed SWV
technique and the HPLC comparative method.
In order to verify whether the excipients from the
pharmaceutical formulation, such as starch, calcium phos-
phate, cellulose, sodium glycolate, or glycerine, interfere in
any way with the method of analysis, recovery studies were
carried out after the addition of known amounts of the pure
drug to the viloxazine formulation. It was verified that the
excipients present in the tablets do not significantly affect
the analysis (Table 3).
The results presently obtained demonstrate the validity of
the proposed method for an accurate determination of
viloxazine in tablets. Furthermore, these results also re-
vealed that both methodologies applied had a comparable
precision and accuracy.
3.5. Determination of Viloxazine in Serum Samples
In order to examine the possibility of applying the newly
proposed analytical method to biological samples, the
quantification of viloxazine in human serumwas also tested.
Calibration equation parameters and validation data are
summarized in Table 2. Serum samples were spiked with
viloxazine in order to achieve final concentrations of 10, 25
and 40 mM.
Square-wave voltammograms obtained from the deter-
mination of viloxazine in human serum samples are
presented in Figure 8. The recoveries obtained were gen-
erally good and are shown in Table 4.
4. Conclusions
The electrochemical oxidation process of viloxazine on a
glassy carbon electrode was studied. The voltammetric and
quantum mechanical analysis performed for viloxazine, as
well as for the model compounds 2-ethoxyanisole and
morpholine, evidenced that the oxidative mechanisms
occurring within these systems are driven by the charge
localization of HOMO and HOMO-1 frontier molecular
orbitals, located on the aromatic ring and morpholine
moiety.
This study enabled the development and proposal of a
voltammetric technique suitable for the determination of
viloxazine in both pharmaceutical formulations and biolog-
ical samples. In fact, the results presently gathered showed
that the proposedmethod is both selective and sensitive, and
does not lead to statistically significant differences when
Table 2. Linearity range, quantification and detection limits and
intra- and interday repeatability for determination of viloxazine,
using the square-wave voltammetric method (SWV), in support-
ing electrolyte and human serum samples.
SWV
Supporting electrolyte Serum
Linearity range (mM) 7 – 45 10 – 45
Calibration graph (n¼ 6)
Intercept (mA) 0.013 0.025
Slope (mA mM1) 49.6 50.9
Correlation coefficient 0.998 0.998
Standard error of intercept 0.021 0.018
Standard error of slope 1.16 1.35
Intraday precision (n¼ 5) [a]
10 mM 2.8 2.3
25 mM 1.6 1.8
40 mM 2.3 2.5
Interday precision (n¼ 5) [a]
10 mM 2.6 2.8
25 mM 2.1 1.9
40 mM 1.8 2.2
LOD (mM) 0.8 1.6
LOQ (mM) 3.2 6.3
[a] Precision as coefficient of variation (CV, %)¼ standard deviation
divided by mean measured concentration 100.
Table 3. Square-wave voltammetric method (SWV), HPLC com-
parative method assay results from viloxazine tablets (Vivalan)
and mean recoveries in spiked tablets.
SWV HPLC
Labeled claim (mg) 100 100
Amount found [a] (mg) 99.2 99.8
RSD (%) 1.9 1.3
Bias (%) 0.8 0.2
t [b] 0.6
F [c] 2.1
Amount added (mg) 20.00
Amount found [a] (mg) 20.09
Recovery (%) 100.4
RSD (%) 1.6
Bias (%) 0.45
[a] Mean of five experiments.
[b] Tabulated t-value for P¼0.05 and eight degrees of freedom is 2.31.
[c] Tabulated F-value for P¼ 0.05 and f1¼ f2¼ 4 is 6.39.
Fig. 8. Differential pulse voltammograms obtained from the
determination of viloxazine in spiked human serum samples. ( ·· · )
Blank serum; (—) 10 mM; (- - -) 25 mM and ( – · – ) 40 mM
viloxazine in human serum samples.
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compared to an established HPLC methodology. The main
advantages of this new methodology is that it may be
directly applied to the analysis of pharmaceutical dosage
forms and biological samples without any special treatment
of the sample (such as separation procedures), since there is
no interference from excipients or other endogenous
substances.
Moreover, the reported results outlook the possibility of
using this technique for monitoring viloxazine for pharma-
cokinetic and pharmacodynamic purposes.
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Table 4. Results obtained for viloxazine analysis from spiked human plasma using the square-wave voltammetric method (SWV).
Viloxazine added (mM) Viloxazine found (mM) Average recovery [a] (%) RSD (%) Bias (%)
10 10.03 100.3 1.2 0.3
25 25.12 100.4 1.1 0.5
40 39.78 99.5 0.8 0.6
[a] Mean of three determinations.
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